<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850081</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM2407</org_study_id>
    <nct_id>NCT02850081</nct_id>
  </id_info>
  <brief_title>Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes</brief_title>
  <acronym>STANCE</acronym>
  <official_title>Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that pre-operative statin use is neuroprotective at maximal
      doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin
      doses for two weeks (12-18 days) prior to CEA using change in performance on a battery
      neuropsychometric tests as outcome measure. Study will recruit patients based on their
      preexisting statin regimen.

      The investigators hypothesize that in asymptomatic CEA patients: 1) Pre-operative statin use
      is neuroprotective against early cognitive dysfunction (eCD) and lowers the risk of early
      mortality. 2) Maximal doses may be essential in achieving optimal neuroprotection against
      eCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carotid endarterectomy (CEA) is a common surgery performed to reduce the risk of stroke in
      patients with carotid artery narrowing. Statins, a class of drugs usually used to lower blood
      cholesterol, may protect the brain after surgery. Specific statins have been shown to protect
      the brain after surgery when compared to others. eCD affects about 25% of patients undergoing
      CEA and about 15% of undergoing asymptomatic CEA. It is associated with marked elevations in
      tissue markers of cerebral injury and is associated with earlier post-CEA mortality. This
      clinically significant, but subtle, cerebral injury is 10 times more common than stroke and
      its mechanism appears to be similarly related to regional hypoperfusion and ischemia. It is
      imperative to determine in a prospective randomized trial whether alteration/increase of
      preoperative statin regimens leads to improved neurologic outcome and an even lower incidence
      of stroke and possibly greater survival.

      In order to optimally design and conduct such a trial it is critical to: 1) explore the
      safety and feasibility of altering statin regimen acutely (approximately 2 weeks) before CEA,
      and 2) clearly establish the neuroprotective outcome of an acute alteration in statin
      regimen. This would promote a better understanding of statin neuroprotection in humans and
      determine the statin treatment that affords the most neuroprotection in patients undergoing
      one of the most commonly performed procedures in the US.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of eCD</measure>
    <time_frame>30 Days: 1) Pre-op vs. Post-CEA Day 1 (12-25 hrs post-op) and 2) Pre-op vs. Post-CEA Day 30</time_frame>
    <description>Neurocognitive assessments ≥2SD worse than reference group in two or more cognitive domains or (b) ≥1.5SD worse than the reference group in all cognitive domains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of early mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Data will be collected by follow up phone call</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <condition>Strokes</condition>
  <arm_group>
    <arm_group_label>Observational - Maximal Dose - ARM 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin &lt;40mg without amlodipine and &lt;20mg with amlodipine; Atorvastatin (&lt;80mg) or Rosuvastatin (&lt;20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin Naive - ARM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Standard of care treatment (one of four):
Simvastatin (to 40mg without amlodipine)
Simvastatin (to 20 mg if currently on amlodipine)
Atorvastatin (to 80mg)
Rosuvastatin (to 20mg)</description>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <other_name>Pre-existing statin regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>A lipid-lowering agent and for prevention of events associated with cardiovascular disease.
10 mg or 80 mg capsules</description>
    <arm_group_label>Statin Naive - ARM 3</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.</description>
    <arm_group_label>Less Than Maximal Dose - ARM 2</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years of age.

          2. Patient is currently on atorvastatin or simvastatin or rosuvastatin or statin naïve
             (no statins in the last 30 days).

          3. The patient has unilateral or bilateral carotid artery stenosis that is considered
             severe (carotid artery diameter reduction ≥ 70%) as defined by:

               1. Peak systolic velocity of at least 230 cm/s plus at least one of these:

               2. End diastolic velocity ≥ 100 cm/s OR

               3. CTA showing ≥ 70% stenosis OR

               4. MRA showing ≥ 70% stenosis

          4. This stenosis has not caused any stroke, transient cerebral ischemia, or other
             relevant neurological symptoms in the past.

          5. The patient's attending doctor(s) (PMD, cardiologist, vascular/neurosurgeon) AND the
             patient have decided to proceed with a CEA to treat the patient's severe carotid
             stenosis.

          6. The patient has no known circumstance or condition likely to preclude 1 year follow-up
             or adherence to the study protocol.

          7. The patient is independent in their Activities of Daily Living at baseline.

          8. Patient has the ability to provide informed consent.

        Exclusion Criteria:

          1. Patient has underlying disease other than atherosclerosis (i.e. autoimmune disease,
             known active malignancy).

          2. Patient has documented dementia or screens out based on abnormal Baseline MoCA (≤25)
             and AD8 (≥2).

          3. Patient's life expectancy is &lt; 12 months.

          4. Patient has advanced renal failure (serum creatinine &gt; 2.5 mg/dL)

          5. Patient has evidence of severe congestive heart failure or has history of end-stage
             cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina).

          6. Patient has history of intolerance or allergic reaction to any statins (myotoxicity,
             hepatic dysfunction, rash, etc.)

          7. Patient has received an investigational drug within 30 days.

          8. Patient is pregnant or lactating.

          9. Patient is currently taking any of the following which have been shown to interact
             with atorvastatin and/or simvastatin and/or rosuvastatin (as per current drug package
             inserts):

               -  Cyclosporine;

               -  HIV Protease Inhibitors/Antivirals (e.g. rotanavir or plus rotanavir, tipranavir,
                  lopinavir, boceprevir, saquinovir, darunavir, fosamprenavir, nelfinavir,
                  efavirenz/tenofobir, atazanavir, simeprevir);

               -  Hep C Protease Inhibitor/Antivirals (e.g. telapravir);

               -  Antibiotics (i.e. cobicistat-containing products like Tybost,
                  rifampin/rifampicin, clarithromycin, telithromycin, erythromycin);

               -  Anti-fungals (i.e. itraconazole, ketoconazole, posaconazole, voriconazole,
                  fluconazole); *Gemfibrozil; Other Fenofibrates (e.g. Tricor, fibric acid);

               -  Niacin &gt; 1g/day or statins in combination with niacin (e.g. Vytorin, Simcor);

               -  Colchicine;

               -  Danazol;

               -  Calcium Channel Blockers: Diltiazem, Varapamil;

               -  Dronedarone;

               -  Amiodarone;

               -  Digoxin;

               -  Ranolazine;

               -  Nefazodone;

               -  Warfarin/Coumadin;

               -  Lomitapide;

               -  Grapefruit juice &gt; 1.2 liters/day (40.5 ounces/day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward S Connolly, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center/New York Presbyterian</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Heyer, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebeca Aragon Garcia, BS</last_name>
    <phone>212-305-4679</phone>
    <email>ra2356@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josephine U Pucci, BA</last_name>
    <phone>2123054679</phone>
    <email>jup2102@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avery Freed</last_name>
      <phone>201-389-0194</phone>
      <email>afreed@valleyhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Sayles</last_name>
      <email>KSAYLES@valleyhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dorothea Altschul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College/The Vascular Group at Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208-3479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryan Kaim</last_name>
      <email>KaimR@mail.amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Sheehan</last_name>
      <email>SheehaA@mail.amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Courtney Warner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph C Darling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260-7016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Gay</last_name>
      <phone>716-440-4231</phone>
      <email>jgay@ubns.com</email>
    </contact>
    <contact_backup>
      <last_name>Reagan O'Toole</last_name>
      <email>rotoole@ubns.com</email>
    </contact_backup>
    <investigator>
      <last_name>Adnan Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Bott</last_name>
      <phone>212-263-2268</phone>
      <email>jacqueline.bott@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Apruzzese</last_name>
      <phone>212-241-8349</phone>
      <email>rebecca.apruzzese@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Milerva Santos</last_name>
      <email>milerva.santos@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>J Mocco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilia Bagiella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeca Aragon Garcia, BS</last_name>
      <phone>212-305-4679</phone>
      <email>ra2356@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Josephine U Pucci, BA</last_name>
      <phone>21123054679</phone>
      <email>jup2102@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Edward S Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise A Caccappolo Van Vliet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaakov Stern, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Buchsbaum</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric J Heyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin L Heinzen-Cox, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University Medical College (Weill)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-4805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruchita Mehta</last_name>
      <email>rum2006@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>E. Sander Connolly</investigator_full_name>
    <investigator_title>Bennett M. Stein Professor of Neurological Surgery, Dept of Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>Carotid endarterectomy</keyword>
  <keyword>CEA</keyword>
  <keyword>stroke</keyword>
  <keyword>asymptomatic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

